Skip to main content
. 2014 Jan 15;7(2):509–520.

Figure 6.

Figure 6

Tim-1-Fc confers protection against cardiac rejection relying on its effect on CD4 Th17 cells. A: Depletion of CD4 T cells diminished the protection conferred by Tim-1-Fc treatment. T-bet-/- recipients were depleted for CD4 T cells and then implanted with Bm12-derived cardiac grafts along with administration of Tim-1-Fc or control IgG as described (n=5 for each study group). B: Administration of Tim-1-Fc provided protection for cardiac grafts against rejection in CD8 depleted T-bet-/- recipients (n=5 for each study group). C: Results for intragraft cytokine expressions by real-time PCR. Data presented here are means ± SD of 3 independent experiments. D: Neutralization of IL-17 completely abolished the protection conferred by Tim-1-Fc (n=5 for each study group). IL-17 was neutralized with a mAb in T-bet-/- recipients after receiving Bm12-derived cardiac grafts along with treatment of Tim-1-Fc or control IgG as described.